person · Reporting owner
Fernandes Prabhavathi
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CapForce Inc.OPGN · Entity 9776 | Director | June 07, 2023 | June 09, 2023 |
| Ocugen, Inc.OCGN · Entity 5550 | Director | November 26, 2024 | December 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CapForce Inc.
Report date June 07, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,000 |
Reported balance
After 2023-06-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-07 · Grant · Acquired 1,500 · Balance 3,000 F1: Represents an award of restricted stock units vesting on the first anniversary of the date of grant, or if earlier, the date of the 2024 annual meeting of stockholders, subject to acceleration and vesting if the director leaves the Board of Directors in connection with a change in control of OpGen, Inc. (the "Company"). F2: The number of restricted stock units and shares reflects the application of the twenty-for-one reverse stock split effected by the Company on January 5, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units vesting on the first anniversary of the date of grant, or if earlier, the date of the 2024 annual meeting of stockholders, subject to acceleration and vesting if the director leaves the Board of Directors in connection with a change in control of OpGen, Inc. (the "Company").
F2: The number of restricted stock units and shares reflects the application of the twenty-for-one reverse stock split effected by the Company on January 5, 2023.
Ocugen, Inc.
Report date November 26, 2024 · Filed December 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2024-11-26 transaction · row 1
1 source rowRow 1 · 2024-11-26 · Purchase · Acquired 10,000 · Balance 10,000 F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9042 to $0.9145. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9042 to $0.9145. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 26, 2024 Filed Dec 2, 2024 21:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | PurchaseCommon Stock | 10,000 | $0.91 | $9,095.00 |
DisclosureSEC source: 0001104659-24-124587 · tm2429834-1_4seq1.xml · nonDerivative · entry 1 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9042 to $0.9145. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:09 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 66,929 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001062993-24-013293 · form4.xml · derivative · entry 1 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,929 Underlying: Common Stock · 66,929 shares Expires 2034-06-28 F1 · derivative.exercise_date: The option vests upon the earlier of (a) June 28, 2025 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 21:28 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 112,205 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001104659-23-070026 · tm2318370-5_4seq1.xml · derivative · entry 1 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,205 Underlying: Common Stock · 112,205 shares Expires 2033-06-09 F1 · derivative.exercise_date: The option vests upon the earlier of (a) June 9, 2024 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:33 UTC | CapForce Inc. OPGN · Entity 9776 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-23-000851 · ownership.xml · nonDerivative · entry 1 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 F1 · security: Represents an award of restricted stock units vesting on the first anniversary of the date of grant, or if earlier, the date of the 2024 annual meeting of stockholders, subject to acceleration and vesting if the director leaves the Board of Directors in connection with a change in control of OpGen, Inc. (the "Company"). F2 · balance_after: The number of restricted stock units and shares reflects the application of the twenty-for-one reverse stock split effected by the Company on January 5, 2023. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:41 UTC | CapForce Inc. OPGN · Entity 9776 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-22-000772 · ownership.xml · nonDerivative · entry 1 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · security: Represents an award of restricted stock units vesting on the first anniversary of the date of grant, or if earlier, the date of the 2023 annual meeting of stockholders, subject to acceleration and vesting if the director leaves the Board of Directors in connection with a change in control of the Company. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 00:56 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 140,091 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001062993-22-014509 · form4.xml · derivative · entry 1 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,091 Underlying: Common Stock · 140,091 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option vests upon the earlier of (a) June 7, 2023 and (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| December 16, 2021 Filed Dec 18, 2021 02:21 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 16,335 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001104659-21-151339 · tm2135818-2_4seq1.xml · derivative · entry 1 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,335 Underlying: Common Stock · 16,335 shares Expires 2031-12-16 F1 · derivative.exercise_date: The option vests monthly in equal installments over three years commencing on January 16, 2022, subject to continued service with Ocugen, Inc. on the applicable vesting dates. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 22:34 UTC | CapForce Inc. OPGN · Entity 9776 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-21-000508 · ownership.xml · nonDerivative · entry 1 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · security: Represents an award of restricted stock units vesting on the first anniversary of the date of grant, or if earlier, the date of the 2022 annual meeting of stockholders, subject to acceleration and vesting if the director leaves the Board of Directors in connection with a change in control of the Company. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:07 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001192482-21-000463 · edgar.xml · derivative · entry 6 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 14,000 shares Expires 2031-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, initially representing a right to purchase a total of 126,000 shares, vests monthly in equal installments over three years commencing on February 1, 2021, subject to continued service with the Company through the applicable vesting dates. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:07 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOption (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001192482-21-000463 · edgar.xml · derivative · entry 5 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,500 Underlying: Common Stock · 19,500 shares Expires 2030-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, initially representing a right to purchase a total of 54,000 shares, vests mothly in equal installments over three years commencing on May 5, 2020, subject to continued service with the Company through the applicable vesting dates. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:07 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommom Stock | 14,000 | $8.19 | $114,660.00 |
DisclosureSEC source: 0001192482-21-000463 · edgar.xml · nonDerivative · entry 4 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.18 to $8.20. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:07 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 14,000 | $1.83 | $25,620.00 |
DisclosureSEC source: 0001192482-21-000463 · edgar.xml · nonDerivative · entry 3 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:07 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 19,500 | $8.21 | $160,095.00 |
DisclosureSEC source: 0001192482-21-000463 · edgar.xml · nonDerivative · entry 2 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.19 to $8.23. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:07 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 19,500 | $0.28 | $5,460.00 |
DisclosureSEC source: 0001192482-21-000463 · edgar.xml · nonDerivative · entry 1 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 22:41 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 126,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001192482-21-000019 · edgar.xml · derivative · entry 1 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2031-01-01 F1 · derivative.exercise_date: The option vests monthly in equal installments over three years commencing on February 1, 2021, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 21:39 UTC | CapForce Inc. OPGN · Entity 9776 | GrantStock Option Award · Derivative | 50,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001079973-20-000843 · ownership.xml · derivative · entry 1 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-09-30 F1 · derivative.exercise_date: The grant of stock options have a one-year vesting schedule, vesting quarterly in equal installments on the first day of each three month period, as long as the Reporting Person continues providing services to the Company on each such vesting date. Read SEC document |
| April 05, 2020 Filed Apr 8, 2020 20:44 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 54,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001192482-20-000280 · edgar.xml · derivative · entry 1 Fernandes Prabhavathi · CIK 0001540883 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2030-04-05 F1 · derivative.exercise_date: The options vest monthly in equal installments over three years commencing on May 5, 2020, subject to continued service with the Company through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.